# Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida

> **NCT05472428** · PHASE1 · COMPLETED · sponsor: **Vinmec Research Institute of Stem Cell and Gene Technology** · enrollment: 11 (actual)

## Conditions studied

- Stem Cell Infusion

## Interventions

- **COMBINATION_PRODUCT:** Autologous bone marrow mononuclear cell transplantation

## Key facts

- **NCT ID:** NCT05472428
- **Lead sponsor:** Vinmec Research Institute of Stem Cell and Gene Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2020-12-25
- **Final completion:** 2021-08-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472428, "Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05472428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*